Gastric/Gastroesophageal Junction Adenocarcinoma

    Actionable Target Abnormality Prevalence Clinical Experience with Targeted Agent
    EGFR Overexpression 30%–90% Cetuximab (EGFR inhibitor):
    • Phase 3, with cisplatin/capecitabine: RR with cetuximab 51% (HER2+), 27% (HER2−), OS 10.7 vs. 9.4 mo (without cetuximab) (1)
    Panitumumab (EGFR inhibitor):
    • Phase 3, with epirubicin/oxaliplatin/capecitabine: OS 8.8 vs. 11.3 mo (without panitumumab) (2)
    HER2 Overexpression/amplification 20%–30% Trastuzumab (HER2 inhibitor) (FDA approved):
    • Phase 3, with cisplatin/5FU/capecitabine: RR 47% (with trastuzumab), OS 13.8 vs. 11.1 mo (without trastuzumab) (3)
    Lapatinib (HER2/EGFR inhibitor):
    • Phase 3, with capecitabine/oxaliplatin: RR 53% (with lapatinib), OS 12.2 vs. mo (without lapatinib) (4)
    Other topics in Targets by Organ Site